Dr.Guttler’s Patient Thyroid Blog Post: Quality of Life After Percutaneous Radiofrequency Ablation

Dr.Guttler’s Patient Thyroid Blog Post: Quality of Life After Percutaneous Radiofrequency Ablation

Dr.Guttler’s Patient Thyroid Blog Post: Quality of Life After Percutaneous Radiofrequency Ablation

Dr.Guttler’s comments:

1. Dr.Valcavi’s group studied Forty patients (35 women and 5 men; age, 54.9 ± 14.3 years) with cold thyroid solitary nodules or a dominant nodule within a normofunctioning multi-nodular goiter (volume range, 6.5 to 90.0 mL) underwent RFA of thyroid nodular tissue under ultrasound real-time assistance.

2. Two years after RFA, nodule volume decreased from 30.0 to 7.9 ml.

3. 80.1 % of initial volume.

4. Symptom score measured on a 0- to 10-cm visual analogue scale (VAS) declined from 5.6 to 1.9 .

5. Cosmetic score (VAS 0–10 cm) declined from 5.7 to 1.9.

6.The data indicates that the achievement of these secondary endpoints is associated with  quality of life improvement.

7. Call me at 310-393-8860 or email to thyroid.manager@thyroid.com about an evaluation for RFA for nodules and small thyroid cancers.

Ask for Alicia.

Dr.G.

 

Health-Related Quality of Life After Percutaneous Radiofrequency Ablation of Cold, Solid, Benign Thyroid Nodules: A 2-Year Follow-Up Study in 40 Patients

ABSTRACT

Objective: We studied the impact of radiofrequency ablation (RFA) on health-related quality of life (HRQL) in patients with benign thyroid nodules (TN) in a 2-year follow-up.

Methods: Forty patients (35 women and 5 men; age, 54.9 ± 14.3 years) with cold thyroid solitary nodules or a dominant nodule within a normofunctioning multi-nodular goiter (volume range, 6.5 to 90.0 mL) underwent RFA of thyroid nodular tissue under ultrasound real-time assistance.

Results: Data are mean and standard deviation. Energy delivered was 37,154 ± 18,092 joules, with an output power of 37.4 ± 8.8 watts. Two years after RFA, nodule volume decreased from 30.0 ± 18.2 mL to 7.9 ± 9.8 mL (-80.1 ± 16.1% of initial volume; P<.0001). Thyroid-stimulating hormone, free triiodothyronine, and free thyroxine levels remained stable. Symptom score measured on a 0- to 10-cm visual analogue scale (VAS) declined from 5.6 ± 3.1 cm to 1.9 ± 1.3 cm (P<.0001). Cosmetic score (VAS 0–10 cm) declined from 5.7 ± 3.2 cm to 1.9 ± 1.5 cm (P<.0001). Two patients became anti-thyroglobulin antibody–positive. Physical Component Summary (PCS)-12 improved from 50.4 ± 8.9 to 54.5 ± 5.3, and the Mental Component Summary (MCS)-12 improved from 36.0 ± 13.3 to 50.3 ± 6.3 (P<.0001 for both score changes).

Conclusion: Our 2-year follow-up study confirms that RFA of benign TNs is effective in reducing nodular volume and compressive and cosmetic symptoms, without causing thyroid dysfunction or life-threatening complications. Our data indicate that the achievement of these secondary endpoints is associated with HRQL improvement, measured both as PCS and MCS.

Abbreviations: fT3 = free triiodothyronine fT4 = free thyroxine HRQL = health-related quality of life MCS-12 = Mental Component Summary-12 PLA = percutaneous laser ablation PCS-12 = Physical Component Summary-12 RF = radiofrequency RFA = radiofrequency ablation SF-12 = Short-Form 12 Health Survey TgAb = anti-thyroglobulin antibody TN = thyroid nodule TRAb = anti-TSH-receptor antibody TSH = thyroid-stimulating hormone US = ultrasound VAS = visual analogue scale

Add Your Comment